Lexington backs Rosetta’s direct pharma deal
The life sciences-focused direct secondaries firm has purchased 20 assets thought to be worth $5-10m each with the backing of Lexington Partners.
24 March 2014•1 min read
SECONDARIES INVESTOR
Register to unlock this content
Daily global secondaries market news and intelligence- Curated insights to keep you ahead of GP-led and LP-led secondaries
- Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
- Access to proprietary research and reports
- Selected fund performance and investor activity data